Losartan Potassium
Product Images NDC 53002-4624

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-4624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530024624)

Packaging label for Losartan Potassium 25 mg tablets by RPK Pharmaceuticals, Inc. The label indicates 100 tablets per bottle, with instructions to take one tablet daily or as directed. It includes prescription-only status and barcode details, with placeholders for clinic name, patient, prescriber, and dates.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for atenolol and losartan potassium. The graph shows an adjusted risk reduction of 13% favoring losartan potassium, with data points presented as solid and dotted lines for losartan potassium and atenolol, respectively.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months for Atenolol and Losartan Potassium. The graph includes an annotation indicating an adjusted risk reduction of 25%, with p=0.001, showing a lower stroke incidence in patients treated with Losartan Potassium over time.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot titled 'Primary Endpoint Events within Demographic Subgroups' presenting hazard ratios and 95% confidence intervals comparing Losartan Potassium and Atenolol event rates. The data is divided into primary composite events and stroke (fatal/non-fatal) events, stratified by various demographic factors including age, gender, race, ISH status, diabetes, and history of cardiovascular disease, with sample sizes indicated. The plot visually compares event rates and hazard ratios to show favorability toward Losartan Potassium or Atenolol for each subgroup.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over time (in months) for Losartan Potassium versus placebo. The graph shows risk reduction and statistical significance, depicting a lower event rate over 48 months for Losartan Potassium compared to placebo.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its molecular arrangement including the chlorine-substituted imidazole ring, hydroxyl group, butyl side chain, biphenyl moiety, and potassium salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.